Androgens, diet, race and obesity are thought to play some roles in the pathogenesis of prostate cancer. We wanted to evaluate if there were any interrelationships between prostate speci®c antigen (PSA), serum testosterone, serum cholesterol, HDL, triglycerides, body mass index (BMI) and race, in older patients with and without prostate cancer (CaP). We evaluated 308 patients referred to urologists in private practice of®ces and clinics with and without prostate cancer with regard to race, serum PSA, age, serum testosterone, full lipid pro®le, height and weight, and stage of cancer. We used multivariate analysis, Fisher's exact test and t-tests as well as logistic regression analysis. Data was analyzed using SPSS computer software, and P-values`0.05 were considered statistically signi®cant. Signi®cantly higher levels of serum testosterone were found in black men with CaP than black men without CaP (526 /728 vs 404 /719, respectively.) We also found signi®cantly higher levels of serum testosterone in white men with CaP than white men without CaP (409 /720 vs 302 /714, respectively, P`0.05). HDL was higher in black men than white men, and triglycerides were higher in white men than black men. Cholesterol was similar across all groups, but BMI was highest in white men with CaP. We also found a signi®cant association between BMI and pathological stage of prostate cancer patients among both black and white men (P`0.05). Our study demonstrated that black men who developed CaP had higher serum testosterone levels, on average, than white men who developed CaP. Furthermore, BMI was highest in white men developing CaP compared to black men, but we found a signi®cant association between pathological stage and BMI in both black and white patients. Although it is controversial whether obesity is considered to be a risk factor for prostate cancer, this small pilot study suggests that BMI may play a role in the progression of the disease once it is established. Prostate Cancer and Prostatic Diseases (2001) 4,101±105.
Introduction
Prostate cancer has become the primary male cancer in the United States with an estimated incidence of 180 000 in the oncoming year. 1 Several observations have been made over the past few years, which have given us a deeper understanding of this disease process. Obesity, increased dietary fat, genetic predisposition, and serum testosterone levels may all play a role in the etiology and the progression of this neoplasm. 2 ± 4 Ross et al had reported serum testosterone levels were higher in young black college students than white students. 5 A follow-up report demonstrated higher levels of 5-alpha reductase in white men compared to Japanese men. 6, 7 Thus, these differences in serum testosterone and dihydrotestosterone could be just one factor as to why the incidence of prostate cancer is highest in black men, followed by white men and then Asian men. However, in longitudinal studies by Heikkila et al 8 and Carter et al 9 there were no associations between serum testosterone levels and those men who were destined to develop prostate cancer.
While a high fat diet has been associated with a higher incidence of prostate cancer, ®ndings from epidemiological studies examining the risk of prostate cancer and obesity have not been consistent. 10 Obesity suggests higher stores of adipose tissue as a source of cholesterol and triglycerides. Since cholesterol is a precursor of androgens, this may be another mechanism by which obesity and a high fat diet may stimulate the progression of prostate cancer. However, several reports demonstrated a decreased risk of prostate cancer with obesity believed to be associated with higher estrogen and lower androgen levels. 11 ± 13 We investigated if there were any associations in 308 patients with and without prostate cancer with regard to race, serum testosterone, body mass index (BMI), lipid pro®le and pathological stage of their disease.
Materials and methods
Four hundred and eighty patients were referred to urologists in clinics and private of®ces for either voiding dif®culties (136), erectile dysfunction (79) or an abnormal prostate speci®c antigen (PSA) digital exam (265) These men had studies of serum testosterone, cholesterol, triglycerides, HDL, BMI and PSA levels over an 18-month period via an approved IRB protocol and informed consent. We excluded patients who were treated with ®nas-teride. Our age range was between 49 and 86 y old, with a mean of 63.3 y. BMI was calculated as weight in kilograms divided by height in meters squared (kg/m 2 ). Our BMI ranged from 21.1 to 32.2 kg/m 2 , with a mean of 27 kg/m 2 . Overweight was de®ned as 26 ± 29.9 BMI and obesity was de®ned as 30 kg/m 2 .
The digital rectal exam (DRE) was performed by one of two senior urologists. Patients with elevated PSA values (PSA greater than 4.0) and/or any palpable nodule, induration or asymmetry of the prostate were further evaluated by an eight core transrectal needle biopsy on the initial 265 patients. An additional 43 biopsies were performed from the sample of 215 men referred for ED or voiding problems because of a suspicious digital exam detected by the urologist. Thirty four of the 308 men undergoing biopsy underwent a second biopsy procedure because of urologist suspicion after a negative ®rst biopsy. This detected an additional six patients with prostate cancer, leading to a total of 111 prostate cancers detected. Transrectal ultrasound (TRUS) was performed using a Bruel and Kjaer 1846 system with a 7 MHz probe.
All blood samples of testosterone and lipid pro®les were drawn between 0800 and 1000 hours to reduce the diurnal variations. Total and free PSA levels were analyzed with Hybritech's Tandem-R PSA and Tandem-R free PSA assay and were performed before digital examination. Since testosterone levels may decrease with age, 91 age-matched controls which were patients not referred to urologists (50 black men and 41 white men) were used to compare hormone levels.
Prostate biospy specimens were read by two pathologists, and graded according to the Gleason score histology, and clinical and pathological tumor stage was assessed according to the 1987 UICC TNM staging system.
Statistical analysis was performed using Fisher's exact test and t-tests, as well as multivariate and logistic regression analysis as appropriate to evaluate any associations. Data was analyzed using SPSS computer softare, and P-values`0.05 were considered to be statistically signi®cant.
Results
Our biopsied patient sample of 308 men consisted of 62 black men and 49 white men with CaP, and 112 black and 85 white men without prostate cancer. Twenty four out of the 62 black men and 29 out of the 49 white men with prostate cancer underwent radical prostatectomy. Pathological staging ranged from T1cNo to T3bN1 (n 53). Fifty-six patients refused surgery and underwent either brachytherapy and/or external beam therapy. Two patients had metastatic disease ( Figure 1) .
PSA values ranged from 4.2 to 17.2 with a mean of 8.2 for black patients and 6.45 for white patients. Gleason scores ranged from 4 to 7, with a mean of 6.4. Multivariate analysis was used to compare the values between race, serum testosterone, cholesterol, PSA, BMI, triglycerides, age and HDL, which are summarized in Table 1 . We found no signi®cant differences in the Gleason scores or age in our sample of black and white patients with prostate cancer.
Using multivariate analysis, serum testosterone and triglyceride levels were found to be signi®cantly different between black and white patients with P-values of 0.002 and 0.001, respectively. The mean serum testosterone of black men was found to be 465 ng/dL with a standard deviation of 22 ng/dL, (control 415 /720) whereas white men had an average serum testosterone level of 356 ng/dL with a standard deviation of 17 ng/dL (control 305 /715). We also found an inverse correlation between serum testosterone and BMI (r 70.28, Figure 1 Flow chart of patient referrals to urologists which lead to radical prostatectomies.
PSA, testosterone, lipids, BMI and race JH Mydlo et al P`0.05) but no relationships between testosterone and PSA or HDL. Black men with CaP had signi®cantly higher levels of testosterone than black men without CaP (526 /728 vs 404 /719, respectively). Similarly, white men with CaP had a signi®cantly higher level of testosterone than white men without CaP (409 /720 vs 302 /714, respectively). Cholesterol levels were similar in all racial groups. Using logistic regression analysis, white men with CaP had the highest body mass index, and both black men and white men had an association between pathological stage and BMI (P`0.05, Table 2 ).
Discussion
We have previously reported that adipose tissue produced a quantitatively and qualitatively greater amount of basic ®broblast growth factor (FGF-2), which affects both prostate and stromal cells, than FGF-2 isolated from BPH or CaP tissue. 14 We suggested that this may be just one mechanism by which prostate cancer progression may be related to obesity and/or a high fat diet. However, since the metabolic products of cholesterol may become the precursors of androgens as well as estrogens, adiposity may also be protective. 12, 13 Our study corroborates previous reports demonstrating higher serum testosterone levels in African-Amercian males compared to white men and Asian men. 5 ± 7 Other investigators have also reported higher serum testosterone in African-American females than white females. 15 Since this androgen diffuses through the placenta, one would expect to ®nd higher levels of the same androgen in black male babies compared to white male babies. Although black men have a higher incidence of prostate cancer than white men, an increased level of PSA, testosterone, lipids, BMI and race JH Mydlo et al serum testosterone has not been shown to be de®nitively associated with an increase risk of prostate cancer. 8, 9 Thus, although the incidence of microscopic adenocarcinoma in young male autopsies is the same worldwide among many different ethnic groups, the differences in the clinical incidence of prostate cancer (CaP) as these patients get older is apparently due to other factors and not testosterone. 16 ± 19 Gustafsson et al reported on a sample of 1782 patients which revealed no signi®cant differences in serum testosterone between patients with or without prostate cancer nor did they ®nd an association between testosterone and serum PSA. 4 However, they reported higher testosterone levels in those patients with higher grade prostate tumors than low grade tumors. 4 Furthermore, Zagars et al reported that serum testosterone levels were a signi®cant determinant for metastatic relapse for irradiated localized prostate cancer. 20 Although there have been several reports that demonstrate a decreased risk of CaP with obesity, Cerhan et al reported that weight gain later in life is associated with a risk of CaP. 17 Giovannucci et al found that although adult body mass and waist and hip circumferences were not appreciably related to the risk of total or advanced prostate cancer, they suggested that childhood obesity may have a strong in¯uence on prostate carcinogenesis. 11 In our study, we found that among those patients who were already diagnosed with prostate cancer, there was an increased pathological stage with increasing BMI (P`0.05). This suggests that obesity may not necessarily increase the risk of incidence of prostate cancer, but may promote it once established.
One of the main weaknesses of our study is a very small sample size. We were only able to correlate pathological stage to BMI in 53 patients. Furthermore, since there were certain patients who elected to undergo brachytherapy and/or external beam therapy instead of surgery, our study was not randomized. It would be interesting to correlate this second group of patients' BMI to their treatment outcomes via follow-up PSA levels.
Another weakness was our inability to obtain serum dihydrotestosterone (DHT) levels from our patients due to the high cost. Since this is the more active form of testosterone intraprostatically, it may have been the more important parameter to measure, either separately or in conjunction with serum testosterone. We were also limited ®nancially to include serum hormone binding globulin levels (SHBG), which can affect the actual active available androgen. This can be criticized as being crucial to estimating the true androgen differences between the groups. 21 Furthermore, although we used the Hybritech assay, there were two different labs involved in the determination of testosterone and lipids, which could have also affected our results.
One may also be critical of the fact that these patients were referred to a urologist, and therefore do not represent a general sampling of patients with other medical problems or tumors. Furthermore, although there were similar demographics between our clinic and private practice patients, we do not know if our results are really indicative of differences between men with prostate cancer and other men who have typical prostates for men in this age group (no benign prostatic hypertrophy, modest BPH, severe BPH). Therefore, we do not know if our results are really generalized to the population of similarly aged men. Interestingly, we did not ®nd any signi®cant differences in testosterone levels in those patients referred for erectile dysfunction.
Another parameter which may have been overlooked is the assessment of ploidy, androgen receptor and p53 expression in the tumor specimen in our comparison to our other parameters. A racial difference in androgen receptors and/or p53 status may have a more profound effect of even small variations of testosterone. 22 ± 24 These factors may demonstrate more signi®cant associations between prostate cancer stage than BMI. In the present study, Gleason score and BMI were independently associated with increasing pathological stage.
Another de®ciency in this study was the omission of body fat distribution, which may be more signi®cant than BMI alone in assessing obesity and prostate cancer. 25, 26 In some studies, CT scans have been used to accurately calculate BMI and body fat distribution, but was cost prohibitive in our study. In addition, this is a small sample to collect data from compared to the other much larger studies which have examined relationships between BMI and cancer. This preliminary study needs to be carried out on a much larger scale to con®rm these initial ®ndings.
Gronberg et al found that high BMI and total food consumption were independent risk factors for prostate cancer. 27 They concluded that dietary habits are important in the development of this tumor. Others have reported the association of reduced caloric intake and/ or fat intake to the inhibition of tumor proliferation and progression. 28, 29 Nutritional supplements like vitamin D and selenium have been reported to have inhibitory effects on prostate cells. 30 Dietary questionnaires, which have certain limitations, could have been employed to estimate the fat content and perhaps the amount of vitamin D or soy consumed. However, it is not uncommon for the individual to vary signi®cantly in his or her statements from what they claim to eat compared to their actual eating habits. 2 Only a prospective study could really attempt to address the role of nutrition in cancer pathogenesis.
In summary, this is a pilot study analyzing a small sample of patients with and without prostate cancer regarding PSA, BMI, and serum testosterone and triglycerides. We found higher testosterone levels in black and white men with prostate cancer compared to their counterparts without prostate cancer. However, black men had a signi®cantly higher serum testosterone compared to white men, whereas white men with prostate cancer had the highest body mass index. Furthermore, we found a signi®cant association among both black and white prostate cancer patients between pathological stage and BMI. From these initial ®ndings we speculate that an increase in body mass index may promote prostate cancer progression as measured by an increase in tumor stage. This study needs to examine a much larger sample of patients with a more heterogenous variation of PSA, Gleason score and measure molecular markers, as well as incorporate a more accurate assessement of body mass index and body fat distribution in order to corroborate or refute these initial ®ndings.
